Table 3.
Immune cell number and phenotype by CKD stage in age and sex-adjusted regression models
| Stage 3 CKD versus eGFR ≥60 |
Stage 4/5 CKD versus eGFR ≥60 |
p for trend | |||
|---|---|---|---|---|---|
| ß | p value | ß | p value | ||
| Number CD3+ | −18.09 | 0.68 | − 163.13 | 0.021* | 0.053 |
| Number CD4+ | −20.49 | 0.46 | −110.87 | 0.013* | 0.024* |
| Number CD8+ | 21.21 | 0.21 | −37.09 | 0.17 | 0.73 |
| CD4+ TNAIVE (%) | 1.75 | 0.29 | 2.19 | 0.41 | 0.23 |
| CD4+ TEFF (%) | −0.31 | 0.33 | 1.09 | 0.032* | 0.29 |
| CD4+ CD127+ (%) | −0.72 | 0.19 | −3.21 | < 0.001* | 0.001* |
| CD4+ CD28- (%) | 0.7 | 0.33 | 1.1 | 0.33 | 0.21 |
| CD4+ CD57+ (%) | 0.32 | 0.47 | 0.32 | 0.65 | 0.46 |
| CD8+ TNAIVE (%) | −2.59 | 0.045* | −3.24 | 0.12 | 0.024* |
| CD8+ TEFF (%) | 4.96 | 0.015* | 4.9 | 0.14 | 0.015* |
| CD8+ CD127+ (%) | −4.66 | 0.009* | −3.59 | 0.21 | 0.019* |
| CD8+ CD28- (%) | 6.04 | 0.002* | 5.14 | 0.1 | 0.004* |
| CD8+ CD57+ (%) | 3.45 | 0.041* | 4.6 | 0.089 | 0.018* |
| Number CD68+ | 23.5 | 0.16 | 0.43 | 0.99 | 0.45 |
| Monocyte 1 (%) | 0.54 | 0.55 | 2.17 | 0.13 | 0.15 |
| Monocyte 2 (%) | −0.19 | 0.29 | −0.25 | 0.38 | 0.22 |
| Monocyte 3 (%) | −0.78 | 0.13 | −1.24 | 0.13 | 0.053 |
Age and sex-adjusted multivariable regression models and trend analyses to test the independent associations between immune profile and CKD stages. *: P value < 0.05. eGFR, estimated glomerular filtration rate derived from the CKD-EPI formula. Stage 3 CKD, eGFR between 30 and 60; stage 4 CKD, eGFR between 15 and 30; stage 5 CKD, eGFR less than 15. Monocyte 1: classical monocytes. Monocyte 2: intermediate monocytes. Monocyte 3: non-classical monocyte